GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » StemRIM Inc (TSE:4599) » Definitions » Revenue per Share

StemRIM (TSE:4599) Revenue per Share : 円38.75 (TTM As of Jan. 2024)


View and export this data going back to 2019. Start your Free Trial

What is StemRIM Revenue per Share?

StemRIM's revenue per share for the three months ended in Jan. 2024 was 円0.00. StemRIM's revenue per share for the trailing twelve months (TTM) ended in Jan. 2024 was 円38.75.

During the past 3 years, the average Revenue Per Share Growth Rate was 2.70% per year. During the past 5 years, the average Revenue Per Share Growth Rate was 12.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for StemRIM's Revenue per Share or its related term are showing as below:

TSE:4599' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -45   Med: 34.55   Max: 79.8
Current: 2.7

During the past 7 years, StemRIM's highest 3-Year average Revenue Per Share Growth Rate was 79.80% per year. The lowest was -45.00% per year. And the median was 34.55% per year.

TSE:4599's 3-Year Revenue Growth Rate is ranked worse than
52.19% of 776 companies
in the Biotechnology industry
Industry Median: 3.65 vs TSE:4599: 2.70

StemRIM Revenue per Share Historical Data

The historical data trend for StemRIM's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StemRIM Revenue per Share Chart

StemRIM Annual Data
Trend Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Revenue per Share
Get a 7-Day Free Trial 2.34 34.66 24.09 0.39 37.55

StemRIM Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 38.75 - - -

Competitive Comparison of StemRIM's Revenue per Share

For the Biotechnology subindustry, StemRIM's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


StemRIM's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, StemRIM's PS Ratio distribution charts can be found below:

* The bar in red indicates where StemRIM's PS Ratio falls into.



StemRIM Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

StemRIM's Revenue Per Share for the fiscal year that ended in Jul. 2023 is calculated as

Revenue Per Share (A: Jul. 2023 )=Revenue (A: Jul. 2023 )/Shares Outstanding (Diluted Average) (A: Jul. 2023 )
=2350/62.584
=37.55

StemRIM's Revenue Per Share for the quarter that ended in Jan. 2024 is calculated as

Revenue Per Share (Q: Jan. 2024 )=Revenue (Q: Jan. 2024 )/Shares Outstanding (Diluted Average) (Q: Jan. 2024 )
=0/61.470
=0.00

Revenue per Share for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円38.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


StemRIM  (TSE:4599) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


StemRIM Revenue per Share Related Terms

Thank you for viewing the detailed overview of StemRIM's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


StemRIM (TSE:4599) Business Description

Traded in Other Exchanges
N/A
Address
7-15 Ayato Bio Incubator 3rd floor, Ayato Asagi 7-chome, Prefecture Ibaraki City, Osaka, JPN, 567-0085
StemRIM Inc is a biotechnology company engaged in developing regeneration-guided medicines. The business activity of the group includes research, development, manufacture, and sales of pharmaceuticals and medical devices and products such as gene therapy that activate stem cells existing in the body and induce regeneration of damaged tissue.

StemRIM (TSE:4599) Headlines

No Headlines